Funding

N-Zyme Biomedical

United States · Biotech · Healthtech

Developing first-in-class therapies targeting pepsin for reflux disease

Visit nzymebio.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series A$4.6MParticipants not disclosed

Investors

No participants disclosed.

Coverage

Jul 22, 2026N-Zyme Biomedical · Series A

Similar companies

Guoke Brain-ComputerBeijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.Undisclosed · Seed
Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
Sourcesnzymebio.com ↗